Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
← catalyst calendarNCT06073821 · readout ≤ 2,020 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
652estimated
Sites
201
Countries
Australia, Austria, Brazil +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-11 | actual | When the study began enrolling |
| Primary completion | Feb 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- CLL
Interventions
- Drug: Sonrotoclax — also filed as BGB-11417
- Drug: Zanubrutinib — also filed as BGB-3111
- Drug: Venetoclax
- Drug: Obinutuzumab
Primary outcomes
what the primary-completion date above is the date OFCohort 1: Progression Free Survival (PFS）
measured Up to approximately 9 years
Cohort 1: Rate of Undetectable Measurable Residual Disease
measured Up to one and a half years
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed